Full Press Release Details
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day.
| Conference Call & Webcast | |
| Friday, June 26th @ 8:00 a.m. ET | |
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13761239 |
Webcast:A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.
About Beyond Air, Inc.Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visitwww.beyondair.net.
CONTACTS:
Corey Davis, Ph.D.LifeSci Advisors, LLCCdavis@lifesciadvisors.com(212) 915-2577